[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466736":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":25,"locations":34,"responsibleParty":54,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pimavanserin","EXPERIMENTAL",null,[13],"Drug: Pimavanserin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","PD related Psychosis",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Ciaran Considine, PhD","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":22},"Richard Darby, MD",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Levi Pettit, BA","CONTACT","6154210569","levi.f.pettit@vumc.org",{"name":32,"role":28,"phone":11,"phoneExt":11,"email":33},"Katie Hay, MS","kaitlyn.r.hay@vumc.org",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Nashville","Tennessee","37212","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-86.78444,36.16589,{"lat":46,"lon":45},[49,51],{"name":27,"role":28,"phone":50,"phoneExt":11,"email":30},"615-421-0569",{"name":32,"role":28,"phone":52,"phoneExt":11,"email":53},"6158757403","katie.orourke@vumc.org",{"type":22,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Daniel Claassen","Assoc Professor",[58],{"name":59,"class":60},"ACADIA Pharmaceuticals Inc.","INDUSTRY","100466736","phase-4-characterization-of-the-serotonin-2a-receptor-selective-pet-tracer-18fmhmz-in-patients-with-neurodegenerative-diseases-100466736",false,"NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","Inclusion Criteria:\n\n* Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants\n* Healthy arm - age and gender matched to patient arm\n* Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.\n* Study partner available for study visits\n\nExclusion Criteria:\n\n* Prior stroke or other uncontrolled serious neurological or medical illness\n* Contra-indication or inability to tolerate MRI scan\n* Use of serotonergic medications in the last 6 weeks\n* Incapable of providing independent consent.\n* Pregnant or breastfeeding women\n* psychosis due to a metabolic, toxic, or primary psychiatric disease\n* Deemed unable to complete neurocognitive testing\n* For PD Participants: current or prior use of pimavanserin\n* Use of antipsychotics in the last 2 weeks",true,"ALL","50 Years","85 Years",{"count":72,"type":73},75,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age\u002Fsex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\\[18F\\]MH.MZ in both populations.",[79,80,81],"Neurodegenerative Diseases","Parkinson Disease","Parkinson Disease Psychosis","2025-08-06",{"date":84,"type":85},"2025-08-12","ACTUAL",{"date":87,"type":85},"2023-01-23",{"date":89,"type":73},"2026-08",{"name":5,"class":6},1]